Treatment of childhood regresive autism with minocycline.

用米诺环素治疗儿童回归自闭症。

• 批准号: 7594593
• 负责人: David M. Neville
• 金额: $ 4.72万
• 依托单位: NATIONAL INSTITUTE OF MENTAL HEALTH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7594593
• 关键词: Acne; Adolescent; Age; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents; Anti-inflammatory; Antibiotics; Astrocytes; Autistic Disorder; Autoimmunity; Behavior; Behavior assessment; Biological Assay; Brain; Child; Childhood; Chronic; Clinical Treatment; Condition; Development; Diagnosis; Diagnostic; Dietary Factors; Disease; Disease regression; Dose; Enrollment; Environmental Risk Factor; Feasibility Studies; Fetal Development; Genes; Goals; Growth Factor; Heritability; Human; Huntington Disease; Immunization; Infection; Inflammation; Inflammatory; Injury; Intervention; Label; Language Development; Mediator of activation protein; Microglia; Minocycline; Monozygotic Twinning; Monozygotic twins; NF-kappa B; Nausea and Vomiting; Neurodegenerative Disorders; Neurodevelopmental Disorder; Nuclear Translocation; Pathology; Patients; Pattern; Penetrance; Pharmaceutical Preparations; Phase; Phase III Clinical Trials; Play; Prevalence; Production; Protocols documentation; Rate; Recording of previous events; Reducing Agents; Research Ethics Committees; Role; Safety; Signs and Symptoms; Subgroup; Time; Tissue Sample; United States Food and Drug Administration; United States National Institutes of Health; Upper arm; Vitamin B6; autism spectrum disorder; autistic children; base; chemokine; cytokine; day; double-blind placebo controlled trial; inhibitor/antagonist; mouse model; neuroinflammation; neurotoxic; prophylactic; response; skills; social; transcription factor

Autism is a neurodevelopmental disorder that results in abnormalities of social and language development and is associated with rigid and repetitive behaviors. Although there is strong evidence of heritability, the involved genes have not been identified. The prevalence of autism spectrum disorders may be as common as 1 in 166. The average concordance rate in monozygotic twins is 70% suggesting that environmental factors play a role in the disease. Subgroups of autistic children seem unusually sensitive to infections, immunizations and dietary factors, but none of these factors has been causally identified with the disease. Nevertheless, autoimmunity has been considered to play a role on the basis of indirect evidence. There is no evidence-based efficacious treatment for autism (Folstein and Rosen-Sheidley, 2001). There is a subgroup of children with autism that appear to develop typically for a period of time, and then lose skills, or regress. A recent study by Vargas and co-workers at Johns Hopkins has demonstrated that the regressive subtype of autism is associated with chronic brain neuroinflammation as exemplified by activation of microglia and astroglia and the abnormal production of inflammatory cytokines and growth factors assayed in both tissue samples (brain banks) and CSF. The authors remarked that these responses were similar to those seen in some neurodegenerative disorders such as amyotrophic lateral sclerosis, and that chronic microglia activation appears to be responsible for a sustained neuroinflammatory response that facilitates the production of multiple neurotoxic mediators. Chronic neuroglial activation could be the result of an abnormal persistence of a fetal development pattern. In this scenario neuroglial activation could play a role in initiating and in maintaining the pathology. Alternatively, neuroglial activation may only be a secondary response to the initiating causal factor(s) and not a direct effector of injury. Since neuroglial activation requires the nuclear translocation of the pro-inflammatory transcription factor NF-kappaB, and since inhibitors of NF-kB with good CNS penetrance are available, the role of neuroinflammation in initiating and sustaining the autistic condition can be probed. The antibiotic minocycline is a powerful inhibitor of microglial activation, apparently through blockade of NF-kB nuclear translocation (Si et al., 2004). Minocycline is neuroprotective in mouse models of amyotrophic lateral sclerosis (ALS) (Van Den Bosch et al. 2002) and Huntingtons disease (Chen, M. et al., 2000) and has been recently shown to stabilize the course of Huntingtons disease in humans over a 2-year period (Bonelli, R.M. et al., 2004). To evaluate the possibility of benefit in autistic children, we propose to conduct an open-label trial of the anti-inflammatory antibiotic minocycline, an agent that reduces inflammation by blocking the nuclear translocation of the proinflammatory transcription factor NF-kB. Minocycline is Food and Drug Administration (FDA)-approved for treatment of a variety of infections and has been widely used for the treatment of adolescent acne. Minocycline is currently in phase III trials for the treatment of Huntingtons disease and amyotrophic lateral sclerosis. This proposal is for an initial 6-month, single-arm, off label, open-label study (with a 3 month extension phase offered to responders) that will evaluate dose safety and efficacy of minocycline in 10 children, ages 3 to 12 years, with a primary diagnosis of autism and a history of developmental regression. The subjects will be evaluated by a diagnostic/behavioral assessment, and the extent of neuroinflammation judged by CSF cytokine/chemokine profiles before and after the 6-month treatment. Subjects will also be given 0.6 mg/kg vitamin B6 twice a day as a prophylactic for possible minocycline induced nausea and vomiting. If the results of this feasibility study are encouraging, we expect to conduct a double-blind, placebo-controlled trial of minocycline therapy. This protocol was approvd by the NIH IRB. Currently 3 patients are enrolled and have received the study drug for one month.

自闭症是一种神经发育障碍，导致社交和语言发育异常，并与刻板和重复的行为有关。虽然有很强的遗传证据，但相关基因尚未被确定。自闭症谱系障碍的患病率可能高达1 / 166。同卵双胞胎的平均一致率为70%，表明环境因素在该病中起作用。自闭症儿童的亚群似乎对感染、免疫和饮食因素异常敏感，但这些因素都没有被认为与自闭症有因果关系。然而，根据间接证据，自身免疫被认为发挥了作用。目前还没有针对自闭症的循证有效治疗方法（Folstein和rosensheidley， 2001）。